About ENTEREG

 

Opioid analgesics, such as morphine, produce pain relief by blocking pain signals through stimulation of opioid receptors located on the surface of the nerves that transmit these signals. Because there are opioid receptors also present in the gastrointestinal (GI) tract, when opioids bind to these receptors, they can disrupt normal GI function that allows for the passage of food through the GI tract and, consequently, can cause patients to experience significant discomfort and pain. These GI side effects include constipation, bloating, nausea and vomiting are often severe enough to be dose-limiting, potentially leading to inadequate pain control.

ENTEREG is a peripherally-acting mu opioid receptor (PAM-OR) antagonist designed to block the adverse side effects of opioid analgesics on the GI tract without blocking their beneficial analgesic effects. 

ENTEREG® (alvimopan) for Postoperative Ileus (POI) - Commercial Indication

ENTEREG was approved by the FDA on May 20, 2008 to accelerate upper and lower gastrointestinal (GI) recovery following partial large or small bowel resection surgery with primary anastomosis. ENTEREG is the first FDA approved therapy for postoperative ileus and is available for short-term use in hospitals registered under the ENTEREG Access Support and Education (E.A.S.E.^TM) program.Please see important safety information, including the boxed warning, for ENTEREG at www.entereg.com.

GSK Collaboration

In April 2002, Adolor entered into a collaboration agreement with GlaxoSmithKline (GSK) for the exclusive worldwide development and commercialization of ENTEREG for certain indications including postoperative ileus (POI)

Adolor and GSK currently distribute ENTEREG for POI in the United States under the E.A.S.E. Program ENTEREG is co-promoted by Adolor and GSK with revenues shared pursuant to contractually agreed percentages. Adolor and GSK also continue to explore additional avenues for the POI indication.